A Phase III clinical trial of PROSTVAC-VF may be in the offing

According to a story on ScienceDaily today, investigators are continuing to plan for a Phase III clinical trial of PROSTVAC-VF — a poxvirus-based prostate cancer “vaccine” — in men with castration-resistant prostate cancer (CRPC). … READ MORE …

New prostate cancer “vaccine” effective in Phase I trial

While we are all waiting for the approval of Provenge, it is worth noting that a research group at the University of Iowa has developed a very different type of prostate cancer treatment based on older technology. … READ MORE …

Social behavior and prostate cancer prevention

In another front-page article this morning, the New York Times discusses the failure of potential patients and the medical community to take seriously the opportunities actually proven to prevent certain types of cancer. … READ MORE …

Prostate cancer news update: Friday, August 21, 2009

In today’s reports we note items related to:

  • Whether add-back estrogen improves cognitive function in men on ADT
  • Exercise and its impact on the side effects of ADT
  • A new technique for delivering prostate cancer “vaccines”
  • The potential of VEGF inhibitors in prostate cancer treatment … READ MORE …

Another new “vaccine” enters clinical trials

According a media release earlier today, Bellicum Pharmaceuticals, Inc. has announced dosing of their first patient in a Phase I/II clinical trial of “BP-GMAX-CD1, a novel pharmacologically regulated dendritic cell vaccine for the treatment of prostate cancer.” … READ MORE …

What’s next in prostate cancer immunotherapy?

Prostate stem cell antigen (PSCA) is a cell surface antigen found in normal human prostate tissue and over-expressed in men who have prostate cancer. … READ MORE …

Monday prostate cancer news report: February 23, 2009

A very early stage clinical study just published in the Journal of the American College of Surgery suggests that “vaccination” with the E75 peptide may be able to prevent or delay recurrences in HLA-A2-positive, high risk prostate cancer patients if the vaccination schedule is completed before biochemical recurrence (as indicated by a rising PSA post-surgery). … READ MORE …

Another breathless media release

A media release from the University of California at San Diego, issued last Wednesday, positively gushes about the potential of glycopeptide-based cancer “vaccine” immunotherapy for prostate cancer. One would like to think that reputable academic institutions could manage to be slightly less hyperbolic about very early stage clinical research. … READ MORE …

Friday’s news and reports: December 12, 2008

Reports and news items today cover potential inaccuracies in using undiagnosed “case control” series, initial clinical trials of a new prostate cancer “vaccine,” and reviews of prostate cancer vaccine development and the management of prostate cancer in the elderly. … READ MORE …

Your weekend news: Saturday, October 4

The most important piece of news today is the publication of the final result of the EORTC 30846 study comparing early and delayed hormone therapy. Other news includes:

  • The hypothesis that fatty acid levels affect prostate cancer risk
  • Prostate cancer risk based on a single PSA level
  • Surgical treatment of men with T3-4 disease
  • Early stage “vaccine” data in a rat model … READ MORE …

Your prostate cancer news update: Saturday, August 16

There is in fact a good deal of news this weekend. Information about four items are provided below and we will discuss additional news items tomorrow. Items in this article include:

  • The relative views of Canadian urologists and radiation oncologists toward PSA screening and treatments for localized disease
  • A complex form of investigational immunotherapy for localized prostate cancer
  • Data suggesting the possibility of a survival benefit resulting from treatment of  hormone refractory prostate cancer patients with docetaxel (Taxotere) + ASA404 (an investigational drug)
  • A new review of psychosocial issues and their impact on management of prostate cancer … READ MORE …

Yet another new Provenge trial

Dendreon has announced initiation of another Phase II trial of Provenge® (sipuleucel-T) for the treatment of advanced prostate cancer. According to the company, this multicenter trial, called ProACT (PROstate Active Cellular Therapy), has begun enrolling 120 patients with metastatic, androgen-independent prostate cancer. … READ MORE …